2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

glioblastoma stem cells

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

2

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-132865
    FTO-IN-3

    		Fat Mass and Obesity-associated Protein (FTO) Cancer
    FTO-IN-3 is a FTO inhibitor that impair self-renewal in glioblastoma stem cells.
    FTO-IN-3
  • HY-122910
    RIPGBM

    		Apoptosis Cancer
    RIPGBM is a selective inducer of apoptosis in glioblastoma multiforme (GBM) cancer stem cells (CSCs) with an EC50 of ≤500 nM .
    RIPGBM
  • HY-B0380A
    Trimebutine maleate

    		Oct3/4 ERK Akt Apoptosis Metabolic Disease Cancer
    Trimebutine maleate is an orally anti-tumor agent. Trimebutine maleate selectively suppresses stemness and proliferation of ovarian cancer stem cells (CSCs). Trimebutine maleate reduces the colonic muscle hypercontractility, modulates gastrointestinal motility, induces apoptosis and can be used for the research of glioma/glioblastoma and irritable bowel syndrome .
    Trimebutine maleate
  • HY-B0106
    Levetiracetam
    1 Publications Verification

    UCB L059

    		 DNA Methyltransferase Neurological Disease Cancer
    Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent .
    Levetiracetam
  • HY-152203
    Mitochondrial respiration-IN-2

    		Others Cancer
    Mitochondrial respiration-IN-2 is the fluorine derivative of Virginiamycin M1 (HY-N6686). Mitochondrial respiration-IN-2 can inhibit mitochondrial translation of glioblastoma stem cells .
    Mitochondrial respiration-IN-2
  • HY-152202
    Mitochondrial respiration-IN-3

    		Mitochondrial Metabolism Cancer
    Mitochondrial respiration-IN-3 is the fluorine derivative of Dalfopristin (HY-A0241). Mitochondrial respiration-IN-3 has cell membrane-permeable. Mitochondrial respiration-IN-3 can inhibit mitochondrial translation of glioblastoma stem cells. Mitochondrial respiration-IN-3 can be used in research of cancer .
    Mitochondrial respiration-IN-3
  • HY-161946
    GBM CSCs-IN-1

    		Apoptosis Cancer
    GBM CSCs-IN-1 (Compound (−)-20), a derivative of rocaglate, is a potent inhibitor of glioblastoma stem cells (GBM CSCs) with an EC50 of 45 nM, functioning by targeting the RNA helicase DDX3. Furthermore, GBM CSCs-IN-1 is also capable of inducing apoptosis .
    GBM CSCs-IN-1
  • HY-132863
    FTO-IN-2

    		Fat Mass and Obesity-associated Protein (FTO) Cancer
    FTO-IN-2 is a FTO inhibitor that impairs self-renewal in glioblastoma stem cells.
    FTO-IN-2
  • HY-B0380AR
    Trimebutine maleate (Standard)

    		Oct3/4 ERK Akt Apoptosis Metabolic Disease Cancer
    Trimebutine (maleate) (Standard) is the analytical standard of Trimebutine (maleate). This product is intended for research and analytical applications. Trimebutine maleate is an orally anti-tumor agent. Trimebutine maleate selectively suppresses stemness and proliferation of ovarian cancer stem cells (CSCs). Trimebutine maleate reduces the colonic muscle hypercontractility, modulates gastrointestinal motility, induces apoptosis and can be used for the research of glioma/glioblastoma and irritable bowel syndrome .
    Trimebutine maleate (Standard)
  • HY-B0106S
    Levetiracetam-d6

    UCB L059-d6

    		 Isotope-Labeled Compounds DNA Methyltransferase Neurological Disease Cancer
    Levetiracetam-d6 is the deuterium labeled Levetiracetam. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent[1][2].
    Levetiracetam-d6
  • HY-B0106S1
    Levetiracetam-d3

    UCB L059-d3

    		 DNA Methyltransferase Neurological Disease Cancer
    Levetiracetam-d3 is the deuterium labeled Levetiracetam. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent[1][2].
    Levetiracetam-d3
  • HY-B0106R
    Levetiracetam (Standard)

    		DNA Methyltransferase Neurological Disease Cancer
    Levetiracetam (Standard) is the analytical standard of Levetiracetam. This product is intended for research and analytical applications. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent .
    Levetiracetam (Standard)
  • HY-115630
    cRIPGBM chloride

    		RIP kinase Caspase Apoptosis Cancer
    cRIPGBM chloride, an orally active, proapoptotic derivative. cRIPGBM can be generated from glioblastoma multiforme (GBM) cancer stem cells (CSCs). cRIPGBM(chloride) targets to receptor-interacting protein kinase 2 (RIPK2) to induce caspase 1-dependent apoptosis. cRIPGBM(chloride) suppresses the formation of RIPK2/TAK1 (prosurvival complex), and increases the formation of RIPK2/caspase 1 (proapoptotic complex). cRIPGBM(chloride) exerts potent anti-tumor activity in vivo in animal models .
    cRIPGBM chloride
  • HY-103693
    NAZ2329
    2 Publications Verification

    		 Phosphatase Cancer
    NAZ2329, the first cell-permeable inhibitor of R5 subfamily of receptor-type protein tyrosine phosphatases (RPTPs), allosterically and preferentially inhibits PTPRZ (IC50=7.5 µM for hPTPRZ1) and PTPRG (IC50=4.8 µM for hPTPRG) over other PTPs. NAZ2329 binds to the active D1 domain and more potently inhibits PTPRZ-D1 fragment (IC50 of 1.1 µM) than the whole intracellular (D1 + D2) fragment (IC50 of 7.5 µM). NAZ2329 can effectively inhibit tumor growth of the glioblastoma cells and suppress stem cell-like properties .
    NAZ2329

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: